138 related articles for article (PubMed ID: 1633300)
1. In vivo studies with chimeric toxins. Interleukin-2 fusion toxins as immunosuppressive agents.
Shapiro ME; Kirkman RL; Kelley VR; Bacha P; Nichols JC; Strom TB
Targeted Diagn Ther; 1992; 7():383-93. PubMed ID: 1633300
[No Abstract] [Full Text] [Related]
2. Recombinant toxins.
Kreitman RJ; Pastan I
Adv Pharmacol; 1994; 28():193-219. PubMed ID: 8080817
[No Abstract] [Full Text] [Related]
3. [Effect of cytotoxin interleukin-2-pseudomonas exotoxin 66 on corneal allograft rejection in mice].
Wu J; Yu J
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov; 29(11):2152-5. PubMed ID: 19923053
[TBL] [Abstract][Full Text] [Related]
4. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
Meneghetti CM; LeMaistre CF
Targeted Diagn Ther; 1992; 7():395-401. PubMed ID: 1633301
[No Abstract] [Full Text] [Related]
5. Treatment with a diphtheria toxin-related interleukin 2 fusion protein prolongs cardiac allograft survival in mice.
Barrett LV; Murphy JR; Strom TB; Kirkman RL
Transplant Proc; 1989 Feb; 21(1 Pt 1):1130-1. PubMed ID: 2650076
[No Abstract] [Full Text] [Related]
6. Two novel therapies for the treatment of cutaneous T-cell lymphoma.
LeMaistre CF
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S7. PubMed ID: 11707856
[No Abstract] [Full Text] [Related]
7. [An experimental study of corneal allograft rejection with cytotoxin IL-2-PE40].
Wu J; Zhou G
Zhonghua Yan Ke Za Zhi; 1995 Sep; 31(5):370-3. PubMed ID: 8706588
[TBL] [Abstract][Full Text] [Related]
8. Protein engineering of diphtheria toxin. Development of receptor-specific cytotoxic agents for the treatment of human disease.
Murphy JR; Lakkis FG; vanderSpek JC; Anderson P; Strom TB
Targeted Diagn Ther; 1992; 7():365-82. PubMed ID: 1633299
[No Abstract] [Full Text] [Related]
9. Recombinant fusion toxins--a new class of targeted biologic therapeutics.
Woodworth TG; Nichols JC
Cancer Treat Res; 1993; 68():145-60. PubMed ID: 8105849
[TBL] [Abstract][Full Text] [Related]
10. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology].
Chiron MF
Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366
[TBL] [Abstract][Full Text] [Related]
11. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?
Bunn PA
Arch Dermatol; 1995 May; 131(5):603-5. PubMed ID: 7537952
[No Abstract] [Full Text] [Related]
12. DAB(389)IL-2 (denileukin diftitox, ONTAK): other potential applications.
LeMaistre CF
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S37-40. PubMed ID: 11707862
[TBL] [Abstract][Full Text] [Related]
13. Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2. I. Studies of in vitro and in vivo efficacy.
Ramadan MA; Gabr NS; Bacha P; Günzler V; Phillips SM
Cell Immunol; 1995 Dec; 166(2):217-26. PubMed ID: 7497523
[TBL] [Abstract][Full Text] [Related]
14. Recombinant toxins as novel therapeutic agents.
Pastan I; Chaudhary V; FitzGerald DJ
Annu Rev Biochem; 1992; 61():331-54. PubMed ID: 1497314
[No Abstract] [Full Text] [Related]
15. Reversal of acute allograft rejection using immunotoxin.
Knechtle SJ; Fechner JH; Stavrou S; Neville DM; Dong Y; Hong X; Tsuchida M; Hamawy MM
Transplant Proc; 1998 Aug; 30(5):2150-1. PubMed ID: 9723422
[No Abstract] [Full Text] [Related]
16. DAB(389)IL-2 (denileukin diftitox, ONTAK): review of clinical trials to date.
Kuzel TM
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S33-6. PubMed ID: 11707861
[TBL] [Abstract][Full Text] [Related]
17. Recombinant toxins for the treatment of cancer.
Kreitman RJ
Curr Opin Mol Ther; 2003 Feb; 5(1):44-51. PubMed ID: 12669470
[TBL] [Abstract][Full Text] [Related]
18. Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.
Kreitman RJ
BioDrugs; 2009; 23(1):1-13. PubMed ID: 19344187
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.
Potala S; Sahoo SK; Verma RS
Drug Discov Today; 2008 Sep; 13(17-18):807-15. PubMed ID: 18678276
[TBL] [Abstract][Full Text] [Related]
20. Immunotoxins and cytokine toxin fusion proteins.
Strom TB; Anderson PL; Rubin-Kelley VE; Williams DP; Kiyokawa T; Murphy JR
Semin Immunol; 1990 Nov; 2(6):467-79. PubMed ID: 2104283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
